Review article · 2026 · Open access

The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases

Jie Tong, Peng Wang, Saiya Ma, Jing Li, Yufei Zhan, Mengxuan Liu, Feng Jin, Guosheng Qu, Chunfu Zheng, Xiaochun Wang, Chuan Wang

Cellular and Molecular Life Sciences, 83(1), 254 · Published 28 April 2026 · DOI 10.1007/s00018-026-06132-1

Open PDFView at the publisherCite this paper

In brief

“The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases” is a 2026 review article by Jie Tong and 10 co-authors, published in Cellular and Molecular Life Sciences. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cellular and Molecular Life Sciences.

Citations
0
References
103
Authors
11

Abstract

Targeted protein degradation (TPD) redefines therapeutic strategies by overcoming the key limitations of traditional occupancy-driven pharmacology. TPD introduces a paradigm shift by using the cell’s intrinsic degradation systems—primarily the ubiquitin–proteasome system (UPS), as well as lysosomal and autophagy pathways—to eliminate disease-causing proteins. Here, we first summarize the research progress of the most advanced TPD platform, proteolysis-targeting chimeras (PROTACs). While most TPD strategies currently rely on a few well-characterized E3 ligases, such as CRBN and VHL, ongoing research aims to expand the ligase repertoire to increase tissue specificity and overcome resistance. Therefore, we also characterized alternative TPD platforms, such as lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), and ribonuclease-targeting chimeras (RIBOTACs), which exploit lysosomal and autophagy pathways, broadening the ability of TPD to reach extracellular and aggregated proteins. Moreover, the application of TPD in oncology, neurodegeneration, immunology, and infectious diseases, with several agents advancing into clinical trials, has also been concluded. On the other hand, the key challenges of TPD remain, including improving bioavailability, minimizing off-target effects, and understanding resistance mechanisms. Overall, as novel chemistries and delivery strategies continue to evolve, TPD represents a powerful and versatile modality with the potential to radically expand the druggable proteome and address unmet medical needs across a wide range of diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Tong, J., Wang, P., Ma, S., Li, J., Zhan, Y., Liu, M., Jin, F., Qu, G., Zheng, C., Wang, X., & Wang, C. (2026). The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases. Cellular and Molecular Life Sciences, 83(1), 254. https://doi.org/10.1007/s00018-026-06132-1

MLA 9

Tong, Jie, et al. “The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases.” Cellular and Molecular Life Sciences, vol. 83, no. 1, 2026, p. 254. https://doi.org/10.1007/s00018-026-06132-1.

Chicago

Tong, Jie, Peng Wang, Saiya Ma, Jing Li, Yufei Zhan, Mengxuan Liu, Feng Jin, et al. 2026. “The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases.” Cellular and Molecular Life Sciences 83 (1): 254. https://doi.org/10.1007/s00018-026-06132-1.

Harvard

Tong, J. et al. (2026) ‘The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases’, Cellular and Molecular Life Sciences, 83(1), p. 254. doi:10.1007/s00018-026-06132-1.

IEEE

J. Tong et al., “The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases,” Cellular and Molecular Life Sciences, vol. 83, no. 1, p. 254, 2026, doi: 10.1007/s00018-026-06132-1.

BibTeX

@article{tong2026degradation,
  title     = {{The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases}},
  author    = {Tong, Jie and Wang, Peng and Ma, Saiya and Li, Jing and Zhan, Yufei and Liu, Mengxuan and Jin, Feng and Qu, Guosheng and Zheng, Chunfu and Wang, Xiaochun and Wang, Chuan},
  journal   = {Cellular and Molecular Life Sciences},
  year      = {2026},
  volume    = {83},
  number    = {1},
  pages     = {254},
  doi       = {10.1007/s00018-026-06132-1},
  url       = {https://doi.org/10.1007/s00018-026-06132-1}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • targeted protein degradation
  • PROTACs
  • ubiquitin-proteasome system
  • E3 ubiquitin ligase
  • cereblon
  • VHL
  • lysosome-targeting chimeras
  • protein aggregation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Tong, J., Wang, P., Ma, S., Li, J., Zhan, Y., Liu, M., Jin, F., Qu, G., Zheng, C., Wang, X., & Wang, C. (2026). The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases. Cellular and Molecular Life Sciences, 83(1), 254. https://doi.org/10.1007/s00018-026-06132-1

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cellular and Molecular Life Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Jie Tong, Peng Wang, Saiya Ma, Jing Li, Yufei Zhan, Mengxuan Liu, Feng Jin, Guosheng Qu, Chunfu Zheng, Xiaochun Wang, Chuan Wang.

What is the DOI of this paper?

10.1007/s00018-026-06132-1, permanently at https://doi.org/10.1007/s00018-026-06132-1. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.